• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Dr Devin Incerti on the Need for Global Value Assessment to Be Adaptable

Video

Devin Incerti, PhD, lead economist, Innovation and Value Initiative, discusses the need for global value assessments to be adaptable for countries that place emphasis on certain values.

Devin Incerti, PhD, lead economist, Innovation and Value Initiative, discusses the need for global value assessments to be adaptable for countries that place emphasis on certain values.

Transcript

Is there a need for a global value assessment to be adaptable to different countries who might place emphasis on certain values?

I think that’s going to be very important. So, while we do have conventional cost-effectiveness and it works quite well, it’s also very context specific. So, take one example: people have come up with this concept called the fair innings argument. It basically says that there may be some cases where individuals live a shorter amount of time. So, if you’re a really sick young infant, if you’re a really sick young kid, your life expectancy might be much shorter than someone who lives a full lifespan. And because of that, we might want some concept of equity where we think about, maybe we want to value the treatments that are going to treat patients that are very sick, very young, maybe those with rare diseases more than we value a treatment that affects the entire population. So, these are all equity considerations that are really, they’re not mathematical. They reflect the value of a particular society.

Related Videos
Screenshot from interview with Andrew Evens, DO
AJMC Q&A with Jason Bellet, Dr Geoffrey Rutledge, and Dan Nardi
Kimberly Westrich, MA, chief strategy officer at the National Pharmaceutical Council
Sam Peasah, PhD, MBA, RPh, director for the Center of High-Value Health Care at the University of Pittsburgh Medical Center
Jawad Haider Butt, MD, PhD
Laura Bobolts, PharmD, BCOP, senior vice president of clinical strategy and growth at OncoHealth
Barry Byrne, MD, PhD, Powell Gene Therapy Center at the University of Florida
JC Scott, CEO and president, PCMA
Caspian Oliai, MD, MS, a medical oncologist and hematologist and medical director of the UCLA Bone Marrow Transplantation Stem Cell Processing Center
Neha Kashalikar, PharmD, director of strategic pharmacy consulting, MassHealth
Related Content
© 2025 MJH Life Sciences
AJMC®
All rights reserved.